NVAX Stock Analysis: Buy, Sell, or Hold?
NVAX - Novavax Inc
$9.49
-0.70 (-6.87%)
▼
5d:
-13.49%
30d:
+1.39%
90d:
-4.91%
WAIT
LOW Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.1/10
Get Alerted When NVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called NVAX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NVAX is down 13.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NVAX is down 13.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NVAX is currently trading at $9.49, which is considered fair relative to its 30-day fair value range of $8.38 to $10.25. From a valuation perspective, the stock is trading at a discount (Forward PE: -37.3) compared to its historical average (35.1). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $8.92, while resistance sits at $11.61. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.11 (+48.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $8.92, while resistance sits at $11.61. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.11 (+48.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.38 -
$10.25
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
Protect Your Profits
Holding NVAX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 48.7% below Wall St target ($14.11)
- WARNING: Recommendation downgraded due to -13.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$8.38 -
$10.25
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.92
Resistance Level
$11.61
Current Trend
Uptrend
Technical data as of
Jun 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-37.29
Wall Street Target
$14.11
(+48.7%)
Revenue Growth (YoY)
-79.1%
Earnings Growth (YoY)
-38.1%
Profit Margin
-14.7%
PE vs Historical
-37.3 vs 35.1
CHEAP
Share & Embed Analysis
Last updated: June 06, 2026 6:51 AM ET
Data refreshes hourly during market hours. Next update: 7:51 AM
Data refreshes hourly during market hours. Next update: 7:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
Advanced NVAX Option Strategies
Professional options setups generated by AI based on today's NVAX price and gamma walls.
